Last Updated: October 3, 2025
Analyzing Management
Public company leadership plays a crucial role in both the initial due diligence and ongoing risk assessment processes for hedge funds and asset managers. ManagementTrack offers a systematic approach that eliminates distractions, highlighting distinct strengths and weaknesses, identifying red and green flags, and drawing a clear connection between CEO actions and financial performance.
CEO Steensberg’s regulatory failures may challenge late-stage execution
Analysis of Zealand Pharma CEO Adam Steensberg
While demonstrating proven financial discipline and partnership success, material regulatory execution failures may leave Adam Steensberg challenged to navigate the company’s critical late-stage clinical and regulatory milestones.
Management evaluated Adam Steensberg’s track record and skillset against the following key factors for ZEAL-DK:
- Resolving regulatory and manufacturing overhangs in the rare disease unit.
- Managing high cash burn to fund the petrelintide program.
- Securing competitive survodutide data to unlock royalty value.
- Delivering pivotal petrelintide data to de-risk Roche partnership.
Adam Steensberg’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
Given the recent CRLs, to what extent does Steensberg’s strength in early-stage pipeline creation come at the expense of the detail-oriented discipline required to successfully navigate late-stage regulatory hurdles?
Question #2
As Steensberg manages the large influx of capital from the Roche deal, will he maintain the cost-cutting discipline from his turnaround or revert to the riskier strategic bets and poor capital allocation that characterized the company’s prior commercial failure?
Question #3
Does Steensberg’s success in executing the strategic pivot and Roche deal create an environment where his vision is unchallengeable, or has his experience with the prior commercial failure made him more receptive to internal dissent when managing high-stakes execution risk?
Why Do Investors Use ManagementTrack?
Q: How does ManagementTrack evaluate ZEAL-DK’s CEO, Adam Steensberg?
A: Through its proprietary career analysis and interviews with former colleagues, ManagementTrack establishes a comprehensive profile of an executive’s track record, core competencies, and potential weaknesses. For Adam Steensberg, this profile is then benchmarked against ZEAL-DK’s critical challenges, including resolving regulatory and manufacturing issues in its rare disease unit, managing high cash burn for the petrelintide program, securing competitive survodutide data to realize royalty value, and delivering pivotal petrelintide data to de-risk the Roche partnership.
Q: What additional methodologies does ManagementTrack employ to predict the C-suite’s impact on future corporate results?
A: ManagementTrack utilizes sophisticated proprietary models to detect and assess abnormal levels of executive evasion during earnings call Q&A sessions. Its platform also scrutinizes all insider transactions to identify outlier activities that are predictive of future stock over- or underperformance. When combined with the ManagementTrack Rating—a predictive 1-to-10 score for each executive—these tools provide investors with a distinct, data-driven perspective on how management is likely to influence company results.
Q: What is the scope of ManagementTrack’s coverage?
A: ManagementTrack provides real-time coverage of the executive C-suite for every publicly traded company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Adam Steensberg
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Zealand Pharma A/S 10Q
- Zealand Pharma A/S 10K
- Zealand Pharma A/S Earnings Calls
- Zealand Pharma A/S Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
